Collection: Highlights of Blood Research, March 26, 2020

The progression of MYC-driven lymphoma requires myC antagonist MNT to inhibit MYC-induced apoptosishttps://doi.org/10.1182/blood.2019003014myC overexpression disorders are associated with the occurrence and malignancy of most human tumorsMYC promotes cell growth and proliferation, but also promotes apoptosis at high levelsRecently, researchers found that the growth of MYC-driven normal and tumor B lymphatic cells depends on MNT, a MYC-related transcription inhibitorgenetic data show that MNT works with MYC-driven apoptosis by inhibiting MYC-driven apoptosis, mainly by reducing apoptosis levels of BIMIn Em-Myc mice, Mnt purified deficiency significantly reduced the incidence of lymphoma by enhancing apoptosis and significantly reducing the precancerous B lymphocyte populationIn particular, inducing Mnt deficiency in all-malignant Em-Myc lymphoma cells can significantly prolong the survival of transplant recipientsLymphoma's survival dependence on MNT suggests that MNT-suppressing drugs can significantly promote THE treatment of MYC-driven tumors by promoting myC-driven intrinsic apoptosis2: Avadomide single drug treatment incurability/ recurrent DLBCLhttps://doi.org/10.1182/blood.2019002395recurrent/refractory diffuse large B-cell lymphoma (R/R DLBCL) treatment options are limited and prognosis is poor, and Avadomide (CC-122) is an immunomodulation and direct anti-tumor effect of the small brain regulatorIn this phase 1 dose amplification trial, the researchers assessed the safety and clinical activity of avadomide monodrug treatment of new R/R DLBCL and transly converted lymphomarecruited a total of 97 r/R DLBCL patients, including 12 cases of convertative lymphoma, to 3-5 mg avadomide, continuous or intermittent mode of administration, until intolerable toxicity, disease progression, or patient withdrawal from the trial82 (85%) patients had 1 or more adverse events (AEs) requiring emergency treatment at level 3-4, the most common being neutrophil reduction (51%), infection (24%), anemia (12%) and feveral neutrophils (10%)Ten per cent of patients have been interrupted by AEsIntermittent 5/7-day therapy improves patient tolerance and reduces the probability and severity of neutrophil reduction, fever neutrophil syphilum and infectionUsing the new disease classification method, the overall remission rate (ORR) for 84 patients with new hair StyleR/R DLBCL was 29%, including 11% full remission (CR)The ORR was 44% in patients with a positive DLBCL, a median progressionless survival period (mPFS) of 6 months, with a full remission rate of 16%, while the ORR for classified negative patients was 19%, mPFS was 1.5 months and CR was only 5%'s New Gene Subtype Classification studyhttps://doi.org/10.1182/blood.2019002414diffuse large B-cell lymphoma is a heterogeneous disease, generally described according to the molecular subtypes of cell source (COO)The researchers tried to classify new patients with DLBCL by distinguishing between tumor microenvironment differencespathway analysis and immunoanti-anti-pleating methods found high B-cell content and strong proliferation signals in subgroup A, and concentrations of T cells, macrophages, and immune/inflammatory signals were found in the B subgroup, which had biological characteristics similar to those published in the DLBCL stratification studyA gene expression classification with 26 gene expression scores was derived from the public data set to distinguish between patients in subgroup A (classifier negative, low immunity) and subgroup B (classifier-positive, high-immune)Avadomide's remission rate and progression-free survival were 44% and 6.2 months, respectively, while the remission rate and progression-free survival of classified-negative patients were 19% and 1.6 months, respectively (HR-0.49)But the new classification does not predict the prognosis of R-CHOP or life-saving immunotherapyEculizumab improves HSCT prognosisin patients with high TA-TMA risk
https://doi.org/10.1182/blood.2019004218supplement overactivation is a high-risk characteristic of patients with transplant-related thrombotic microvascular lesions (TA-TMA) with HSCT transplantation Recently, researchers examined the effectiveness of the supplement blocker eculizumab in treating patients with high TA-TMA and multiple organ damage risk HSCT previously reported patients with high TA-TMA risk, who had never been treated, had a 1-year survival rate of only 16.7 percent after HSCT, while those with eculizumab were treated with similar patients, with an increase in the 1 stile of HSCT to 66 percent Patients with a response can benefit from short-term intensive eculizumab treatment, which requires an average of 11 doses of eculizumab At the median 66 days, treatment was terminated due to TA-TMA subsidy Individuals with elevated supplement activation of blood sC5b-9 were less likely to respond to treatment, and patients with intestinal bleeding were ecurizumab with a faster rate of removal, and patients in these two groups needed more doses of eculizumab treatment and had a lower 1-year survival rate (44% vs 78%) Source: Network